Amgen asks FDA to approve biosimilar drug
By Staff Report / Wednesday, November 25th, 2015 / Health Care & Life Science, Latest news, Top Stories / Comments Off on Amgen asks FDA to approve biosimilar drug
Amgen submitted an application to the Food and Drug Administration for approval of its biosimilar drug ABP 501 on Nov. 25. ABP 501 is designed as a lower-cost version of Humira, which is approved to treat nine conditions including arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based AbbVie, typically costs $20,000 per year Read More →
Study shows Amgen’s new biosimilar cancer drug safe, effective
By Staff Report / Wednesday, September 23rd, 2015 / Latest news, Technology, Top Stories / Comments Off on Study shows Amgen’s new biosimilar cancer drug safe, effective
Pharmaceuticals Amgen and Allergan announced positive Phase 3 study results of their new drug ABP 215 on Sept. 23. The drug, used to treat lung cancer, is being developed as a biosimilar to Roche Holding AG’s Avastin. ABP 215 showed clinical safety and effectiveness compared to Avastin. “Lung cancer is the leading cause of cancer Read More →
Amgen buys biotech company, partners with another
By Staff Report / Wednesday, September 16th, 2015 / Health Care & Life Science, Latest news, Technology, Top Stories, Tri-County Public Companies / Comments Off on Amgen buys biotech company, partners with another
Thousand Oaks-based biopharmaceutical giant Amgen bought a Netherlands-based company and partnered with a Monrovia-based company in an effort to fend off competitors. Amgen announced Sept. 16 that it will buy Dezima, a biotech company focused on developing new treatments for dyslipidemia, a disease where a person has an abnormal amount of lipids in their blood. Read More →
